Institution
Broad Institute
Nonprofit•Cambridge, Massachusetts, United States•
About: Broad Institute is a nonprofit organization based out in Cambridge, Massachusetts, United States. It is known for research contribution in the topics: Population & Genome-wide association study. The organization has 6584 authors who have published 11618 publications receiving 1522743 citations. The organization is also known as: Eli and Edythe L. Broad Institute of MIT and Harvard.
Papers published on a yearly basis
Papers
More filters
••
German Cancer Research Center1, Heidelberg University2, Max Planck Society3, University of Cambridge4, Russian Academy5, McGill University6, University of Amsterdam7, University of Würzburg8, University Hospital Heidelberg9, University of Tübingen10, Stanford University11, Harvard University12, Broad Institute13, University of Toronto14, New York University15, Johns Hopkins University16, Boston Children's Hospital17, University of Münster18, University of Düsseldorf19, McGill University Health Centre20
TL;DR: Recurrent activating mutations in FGFR1 and PTPN11 and new NTRK2 fusion genes in non-cerebellar tumors and new BRAF-activating changes were observed, indicating that pilocytic astrocytoma is predominantly a single-pathway disease.
Abstract: Pilocytic astrocytoma, the most common childhood brain tumor, is typically associated with mitogen-activated protein kinase (MAPK) pathway alterations. Surgically inaccessible midline tumors are therapeutically challenging, showing sustained tendency for progression and often becoming a chronic disease with substantial morbidities. Here we describe whole-genome sequencing of 96 pilocytic astrocytomas, with matched RNA sequencing (n = 73), conducted by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. We identified recurrent activating mutations in FGFR1 and PTPN11 and new NTRK2 fusion genes in non-cerebellar tumors. New BRAF-activating changes were also observed. MAPK pathway alterations affected all tumors analyzed, with no other significant mutations identified, indicating that pilocytic astrocytoma is predominantly a single-pathway disease. Notably, we identified the same FGFR1 mutations in a subset of H3F3A-mutated pediatric glioblastoma with additional alterations in the NF1 gene. Our findings thus identify new potential therapeutic targets in distinct subsets of pilocytic astrocytoma and childhood glioblastoma.
657 citations
••
Princess Margaret Cancer Centre1, National Institutes of Health2, Monash University3, Merck & Co.4, Institute of Cancer Research5, Structural Genomics Consortium6, Pfizer7, GlaxoSmithKline8, Eli Lilly and Company9, Boehringer Ingelheim10, University of Dundee11, Scripps Research Institute12, Mayo Clinic13, Janssen Pharmaceutica14, Novartis15, University of North Carolina at Chapel Hill16, Harvard University17, Takeda Pharmaceutical Company18, Austrian Academy of Sciences19, Icahn School of Medicine at Mount Sinai20, Broad Institute21, Vertex Pharmaceuticals22, Bayer HealthCare Pharmaceuticals23, European Bioinformatics Institute24, University of Toronto25, University of California, San Francisco26, Karolinska University Hospital27, Medical University of Vienna28, CHDI Foundation29, University of Minnesota30, Simon Fraser University31
TL;DR: A community-driven wiki resource to improve quality and convey current best practice on chemical probes, and to help address shortcomings of poor quality or that are used incorrectly generate misleading results.
Abstract: Chemical probes are powerful reagents with increasing impacts on biomedical research. However, probes of poor quality or that are used incorrectly generate misleading results. To help address these shortcomings, we will create a community-driven wiki resource to improve quality and convey current best practice.
656 citations
••
University of Texas Southwestern Medical Center1, Boston Children's Hospital2, University of California, San Diego3, Howard Hughes Medical Institute4, Baylor College of Medicine5, Washington University in St. Louis6, Reata Pharmaceuticals7, Utrecht University8, Cancer Research UK9, Broad Institute10, Harvard University11, Columbia University12, University of California, Berkeley13
TL;DR: Through the characterization of a domain of beclin 1 that interacts with HIV-1 Nef, an autophagy-inducing peptide is developed that has potential efficacy in the treatment of human diseases.
Abstract: The lysosomal degradation pathway of autophagy has a crucial role in defence against infection, neurodegenerative disorders, cancer and ageing. Accordingly, agents that induce autophagy may have broad therapeutic applications. One approach to developing such agents is to exploit autophagy manipulation strategies used by microbial virulence factors. Here we show that a peptide, Tat-beclin 1-derived from a region of the autophagy protein, beclin 1, which binds human immunodeficiency virus (HIV)-1 Nef-is a potent inducer of autophagy, and interacts with a newly identified negative regulator of autophagy, GAPR-1 (also called GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya or West Nile virus. Thus, through the characterization of a domain of beclin 1 that interacts with HIV-1 Nef, we have developed an autophagy-inducing peptide that has potential efficacy in the treatment of human diseases.
656 citations
••
TL;DR: Analyzing five cancer types occurring among several individuals found that three types of epithelial tumors exhibited high rates of element movement relative to brain and blood cancers, and Whole-genome sequencing provides evidence for somatic insertions in colorectal, prostate, and ovarian cancers.
Abstract: Transposable elements (TEs) are abundant in the human genome, and some are capable of generating new insertions through RNA intermediates. In cancer, the disruption of cellular mechanisms that normally suppress TE activity may facilitate mutagenic retrotranspositions. We performed single-nucleotide resolution analysis of TE insertions in 43 high-coverage whole-genome sequencing data sets from five cancer types. We identified 194 high-confidence somatic TE insertions, as well as thousands of polymorphic TE insertions in matched normal genomes. Somatic insertions were present in epithelial tumors but not in blood or brain cancers. Somatic L1 insertions tend to occur in genes that are commonly mutated in cancer, disrupt the expression of the target genes, and are biased toward regions of cancer-specific DNA hypomethylation, highlighting their potential impact in tumorigenesis.
655 citations
••
TL;DR: MTOR signaling has a critical role in the pathogenesis of HCC, with evidence for the role of RICTOR in hepato-oncogenesis, and a rationale for targeting the mTOR pathway in clinical trials in HCC is established.
655 citations
Authors
Showing all 7146 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eric S. Lander | 301 | 826 | 525976 |
Albert Hofman | 267 | 2530 | 321405 |
Frank B. Hu | 250 | 1675 | 253464 |
David J. Hunter | 213 | 1836 | 207050 |
Kari Stefansson | 206 | 794 | 174819 |
Mark J. Daly | 204 | 763 | 304452 |
Lewis C. Cantley | 196 | 748 | 169037 |
Matthew Meyerson | 194 | 553 | 243726 |
Gad Getz | 189 | 520 | 247560 |
Stacey Gabriel | 187 | 383 | 294284 |
Stuart H. Orkin | 186 | 715 | 112182 |
Ralph Weissleder | 184 | 1160 | 142508 |
Chris Sander | 178 | 713 | 233287 |
Michael I. Jordan | 176 | 1016 | 216204 |
Richard A. Young | 173 | 520 | 126642 |